• About
  • Subscribe
  • Advertise
  • Contact
Saturday, December 13, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home News

EssilorLuxottica completes GrandVision deal

by Myles Hume
July 1, 2021
in Business, Company updates & acquisitions, International, News
Reading Time: 3 mins read
A A
EssilorLuxottica GrandVision deal

The late Mr Leonardo Del Vecchio. Image: EssilorLuxottica

Share on FacebookShare on Twitter

EssilorLuxottica has completed the acquisition of optical retail giant GrandVision, ending uncertainty sparked by a legal ruling that granted the eyewear giant the option to walk away from the €7.3 billion (AU$11.2 billion) deal altogether.

On 29 June, EssilorLuxottica announced it would complete the purchase of HAL’s majority 76.72% stake in GrandVision. The deal took place on Thursday 1 July as per the terms of the original agreement signed almost two years ago.

“After assessing all our options, we have made the decision to proceed with the completion of the deal without further delay. The strategic rationale of the transaction remains strong and unchanged, and after two years of efforts and relentless work, we are now ready to turn a page and start a new chapter of EssilorLuxottica’s history, with GrandVision,” EssilorLuxottica CEO Mr Francesco Milleri and deputy CEO Mr Paul du Saillant said.

“In doing so, we will use the learnings and experience gathered over the past years to ensure GrandVision and its 37,000 talented employees are integrated successfully. As the industry returns to growth following the pandemic, we believe this is the perfect time to expand our retail network, so that we can engage more effectively with consumers and thus raise the visibility and quality of the entire industry. This will benefit all stakeholders, including our customers to whom we remain fully committed.”

GrandVision operates around 7,000 stores across 40 countries.

By acquiring the shares owned by HAL – a Dutch investment group – EssilorLuxottica is expected to drastically increase its footprint by around 7,000 stores across 40 countries.

As a result of the completion of the transaction, EssilorLuxottica acquired “predominant control” over GrandVision and is under an obligation to launch a mandatory public offer for all outstanding shares, in accordance with the applicable Dutch public offer rules. EssilorLuxottica’s objective is to delist GrandVision from Euronext Amsterdam.

It comes after the Turkish Competition Authority became the final jurisdiction to clear the deal on 10 June.

However, 11 days later on 21 June, the transaction was in doubt after arbitration proceedings between the entities ruled in the favour of EssilorLuxottica.

The legal saga was sparked by EssilorLuxottica after it grew concerned about how GrandVision managed its business during the COVID-19 crisis. GrandVision later requested an arbitral tribunal to confirm among other things, that it was is not in material breach of its agreement with EssilorLuxottica. HAL has also initiated proceedings.

The tribunal ruled that EssilorLuxottica had the option to terminate the acquisition of GrandVision “due to GrandVision’s material breaches of its obligations to EssilorLuxottica”.

Prior to confirming it would go ahead with the acquisiton, EssilorLuxottica stated it would review its options and it “regretted that GrandVision’s misconduct has led us to this situation”.

With the deal now certain, EssilorLuxottica will purchase HAL’s interest in GrandVision for €28.42 per share.

More reading

EssilorLuxottica secures final GrandVision clearance; unveils sustainable acetate plans

European Commission clears EssilorLuxottica’s GrandVision takeover, 350 stores to be divested

EssilorLuxottica and Facebook are developing Ray-Ban smartglasses

Tags: acquisiitonagreementdealEssilorLuxotticaGrandVisionHAL

Related Posts

Globally, more than 196 million people have AMD. Image: Jum/stock.adobe.com.

Aussie study pinpoints key genetic changes in AMD risk

by Staff Writer
December 12, 2025

Australian researchers have for the first time pinpointed specific genetic changes that increase the risk of severe, sight-threatening forms of...

Almost 90% of medical trainees have rated their training highly in the latest MTS. Image: Ai design/stock.adobe.com.

Medical trainees point to unacceptable behaviour in health system

by Staff Writer
December 12, 2025

Medical trainees have rated the quality of their medical training highly in the latest Medical Training Survey, but the rate...

A new Certificate in Advanced Ocular Therapeutics will equip optometrists for regulatory changes currently under consideration by OBA. Image: ACO

Registrations open for new and returning ACO certificate courses

by Staff Writer
December 11, 2025

Registrations are now open for the Australian College of Optometry (ACO) certificate courses in 2026, including a new Certificate in...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited